Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Alaunos Therapeutics (TCRT) over the last 11 years, with Q3 2025 value amounting to $2.2 million.

  • Alaunos Therapeutics' Shares Outstanding (Diluted Average) rose 3633.33% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 3633.33%. This contributed to the annual value of $1.6 million for FY2024, which is 10.75% up from last year.
  • Alaunos Therapeutics' Shares Outstanding (Diluted Average) amounted to $2.2 million in Q3 2025, which was up 3633.33% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Alaunos Therapeutics' Shares Outstanding (Diluted Average) peaked at $215.1 million during Q3 2022, and registered a low of $1.6 million during Q2 2023.
  • For the 5-year period, Alaunos Therapeutics' Shares Outstanding (Diluted Average) averaged around $74.2 million, with its median value being $1.9 million (2025).
  • In the last 5 years, Alaunos Therapeutics' Shares Outstanding (Diluted Average) tumbled by 9925.64% in 2023 and then surged by 3633.33% in 2025.
  • Quarter analysis of 5 years shows Alaunos Therapeutics' Shares Outstanding (Diluted Average) stood at $214.4 million in 2021, then crashed by 93.25% to $14.5 million in 2022, then crashed by 88.95% to $1.6 million in 2023, then increased by 0.11% to $1.6 million in 2024, then soared by 36.33% to $2.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $2.2 million in Q3 2025, compared to $1.7 million in Q2 2025 and $1.6 million in Q1 2025.